<DOC>
	<DOCNO>NCT00799682</DOCNO>
	<brief_summary>The purpose study determine difference ocular sign symptom subject ' eye use Xalatan® 0.005 % versus Travatan Z® 0.004 % base outcome subject assessment clinical assessment patient Ocular Hypertension Glaucoma mild moderate dry eye baseline accordance Oxford Grading Scale .</brief_summary>
	<brief_title>Exploratory Study Comparing Signs Symptoms Patients With Ocular Hypertension Glaucoma Using Xalatan R® Travatan Z®</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Male Female 18 year age old Only patient satisfy inform consent requirement may include study Be likely complete entire course study comply study drop regimen , guideline visit Able understand drop instruction instill study drops Patients must monotherapy Ocular Hypertension Glaucoma agree washout period , accord Appendix E Patient Ocular Hypertension , chronic OpenAngle Glaucoma , chronic AngleClosure Glaucoma patent iridotomy/iridectomy , Pseudo Exfoliate Glaucoma , Pigmentary Glaucoma eye screen visit . Patients use systemic nonglaucoma medication know low IOP may include , stable dose &gt; 30 day prior screen visit agree maintain regimen throughout course study . Patients use nonprescription eye drop prescription topical eye drop dry eye may include , stable dose 30 day prior screen visit agree maintain regimen throughout course study . Patients wear contact lens maintain wear pattern duration study Best Corrected LogMar VA ≤0.70 = ( 20/100 Snellen equivalent ) Hyperemia Grading ≤2 IOP ≤ 30 mmHg Shirmers 3mm 9.75mm Tear breakup time ( TBUT ) 4 second 9seconds Must meet Biomicroscopic Criteria eye define Oxford Grading Scale Generally good stable overall health Females childbearing potential ( surgically sterilize define oneyear postmenopausal ) exclude participation study meet one follow condition : They currently pregnant , They positive result urine pregnancy test Screening Visit , They intend become pregnant study period , They breastfeed , They use highly effective birth control measure : Hormonaloral , implant , transdermal injected contraceptive ; Mechanicalspermicide conjunction barrier condom diaphragm IUD Note : All female childbearing potential must consent urine pregnancy test Screening . Females childbearing potential instructed inform investigator become pregnant study . Should occur , Investigator shall immediately contact Sponsor . For nonsexually active female , abstinence may regard adequate method birth control ; however , patient becomes sexually active study , must agree use adequate birth control method define remainder study . Patients currently investigational agent discontinue within 30 day prior Screening Visit Uncontrolled systemic disease Patients known medical history allergy sensitivity prostaglandin drug ( topical and/or systemic ) Patient history refractive surgery History ocular trauma within past six month either eye History ocular infection ocular inflammation within past three month either eye History clinically relevant progressive retinal disease retinal degeneration , diabetic retinopathy , retinal detachment either eye base assessment Investigator History severe ocular pathology accord Oxford Grading Scale great Grade 4 dry eye ) either eye Intraocular surgery within past six month determine patient history and/or examination either eye . Ocular laser surgery Punctal Cautery within past three month determine patient history and/or examination either eye Punctal Plugs insertion ≤ 7 day prior ( Visit 1 ) Screening Any abnormality prevent reliable applanation tonometry either eye . Contraindication pupil dilation patient cycloplegia Patients bestcorrected visual acuity score worse 0.70 LogMar ( 20/100 ) score either eye Patients ≤30 day stable dose regimen Screening Visit medication substance administer route use chronic basis History StevensJohnson Syndrome Ocular Pemphigoid History liver disease Severe clinical vitamin deficiency history vitamin overdose Highly variable selfadministration overthecounter vitamin/herbal product Any steroid use within past 30 day Corneal pathology , could , , cause ocular surface disorder Visual Field loss opinion Investigator functionally significant evidence progress visual field loss within last year prior ( Visit 2 ) Baseline/Randomization Patient condition situation , investigator 's opinion , may put subject significant risk , may confound study result , may interfere significantly subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Dry Eye</keyword>
	<keyword>Monotherapy Ocular Hypertension , Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
	<keyword>Chronic Open-Angle Glaucoma</keyword>
	<keyword>Chronic Angle-Closure Glaucoma</keyword>
	<keyword>Iridotomy</keyword>
	<keyword>Iridectomy</keyword>
	<keyword>Pseudo Exfoliate</keyword>
	<keyword>Pigmentary Glaucoma</keyword>
	<keyword>Systemic Non-Glaucoma Medications</keyword>
	<keyword>Hyperemia</keyword>
</DOC>